US · SCLXW
Scilex Holding Company
- Sector
- Healthcare · Drug Manufacturers - General
- Headquarters
- Palo Alto, CA 94303
- Website
- scilexholding.com
Price · as of 2024-12-31
$0.20
Market cap 1.37M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $0.00 | $0.00 | |||
| 2022 | $0.00 | $0.00 | |||
| 2023 | $0.00 | $0.00 | |||
| 2024 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Scilex Holding Company's (SCLXW) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $0.20
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| SCLXW | Scilex Holding Company | $0.20 | 1.37M | — | — | — | — | — | — | — | — | — | — | 70.51% | -147.37% | -128.66% | 39.83% | 80.83% | -74.96% | -0.20 | -42.48 | 0.16 | 0.11 | -0.52 | -5668.00% | 2107.00% | -19198.00% | — | 0.07 | -18.75% | — | 0.00% | — | — | — | — | — |
| ACET | Adicet Bio, Inc. | $7.25 | 69.44M | — | — | — | — | -0.60 | 0.37 | — | 0.81 | — | 0.37 | 0.00% | — | — | -65.65% | -433.12% | -54.79% | 0.09 | -31903.75 | 9.29 | 9.09 | 0.35 | -5982.00% | — | -477.00% | -133.68% | -4.76 | -317.32% | 0.00% | 0.00% | 0.00% | 0.70 | 0.95 | — | -2.95 |
| ADAG | Adagene Inc. | $2.96 | 111.61M | +945% | -54% | — | +2,625% | -2.19 | 1.45 | 708.59 | -0.20 | -2.88 | 1.45 | -797.49% | -34835.42% | -32386.45% | -55.21% | 216.17% | -32.61% | 0.37 | -42.20 | 2.30 | 2.23 | 2.11 | 7593.00% | -9943.00% | 419.00% | -40.66% | -0.78 | 178.88% | 0.00% | 0.00% | 0.00% | -0.18 | -0.22 | 62.29 | -4.41 |
| ASRT | Assertio Holdings, Inc. | $11.66 | 74.82M | +1,017% | +6,046% | -82% | +159% | -3.44 | 0.61 | 0.59 | 2.82 | — | 1.83 | 68.61% | -19.59% | -17.27% | -16.66% | -29.57% | -7.56% | 0.33 | -8.05 | 1.77 | 1.34 | -2.01 | -9507.00% | -1783.00% | -4608.00% | 35.54% | 0.23 | 31.91% | 0.00% | 0.00% | 0.47% | -0.59 | 0.55 | 0.12 | -2.51 |
| CRVO | CervoMed Inc. | $3.99 | 36.92M | — | — | — | — | -1.10 | 0.46 | — | 1.16 | -0.75 | 0.46 | 0.00% | — | — | -69.95% | 26851.40% | -61.41% | 0.00 | — | 11.11 | 10.61 | 0.49 | 14634.00% | — | 12189.00% | -92.65% | -4.26 | 24352.48% | 0.00% | 0.00% | 6.76% | 1.16 | 1.28 | — | 0.16 |
| DXR | Daxor Corporation | $11.86 | 59.76M | +2,657% | +20% | -33% | — | 72.23 | 1.08 | 18.18 | 19.18 | 88.61 | 1.08 | 100.00% | 29.16% | 25.17% | 1.54% | 1.74% | 1.50% | 0.02 | 7.30 | 0.17 | 0.09 | 0.35 | 8152.00% | -9384.00% | -10070.00% | 0.07% | 0.23 | 0.07% | 0.00% | 0.00% | 0.07% | 63.52 | 1536.03 | 18.52 | 28.75 |
| GANX | Gain Therapeutics, Inc. | $2.61 | 100.39M | +1,143% | — | — | — | -2.11 | 5.86 | — | -1.64 | — | 5.97 | 0.00% | — | — | -204.95% | 729.11% | -132.83% | 0.09 | — | 2.97 | 2.85 | 0.48 | -4795.00% | -10000.00% | 8.00% | -43.93% | -4.83 | 677.01% | 0.00% | 0.00% | 0.00% | -1.64 | -1.76 | — | -8.76 |
| LITS | Lite Strategy, Inc. | $1.13 | 41.55M | +12,712% | — | — | — | -1.77 | 1.66 | — | -0.60 | — | 1.66 | 0.00% | — | — | -63.84% | 545.04% | -53.45% | 0.00 | — | 13.50 | 13.30 | 1.05 | -18951.00% | -10000.00% | -5871.00% | -73.96% | -15.39 | 650.87% | 0.00% | 0.00% | 50.76% | -0.58 | -0.49 | — | -20.49 |
| NRXP | NRx Pharmaceuticals, Inc. | $1.86 | 32.15M | — | — | — | — | -0.91 | -0.98 | — | -1.16 | — | -0.98 | 0.00% | — | — | 143.76% | 156.03% | -458.25% | -0.28 | -18.26 | 0.15 | 0.07 | -0.21 | -3995.00% | — | -5089.00% | -46.61% | -0.49 | 84.23% | 0.00% | 0.00% | 0.00% | -1.42 | -2.63 | — | -130.11 |
| RVMD | Revolution Medicines, Inc… | $102.02 | 19.72B | — | — | — | — | -17.08 | 11.84 | — | -16.01 | -25.80 | 12.38 | 0.00% | — | — | -58.07% | 1908.09% | -46.06% | 0.10 | -48.80 | 7.14 | 6.97 | 0.21 | 6620.00% | — | 6094.00% | -4.73% | -3.09 | 1474.57% | 0.00% | 0.00% | 0.00% | -14.76 | -19.10 | — | 13.58 |
About Scilex Holding Company
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid therapies for patients with acute and chronic pain. The company's principal product includes ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102 or SEMDEXA, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase 3 clinical trial to treat lumbosacral radicular pain; SP-103 for the treatment of low back pain, which is in Phase 2 clinical trails; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia that is in Phase 1 clinical trials. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
- CEO
- Henry H. Ji
- Employees
- 115
- Beta
- 1.37
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $0.20) − 1 = — (DCF, example).